Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. Mast cell stabilizer - Wikipedia
Mast cell stabilizer - Wikipedia
From Wikipedia, the free encyclopedia
Category of pharmaceutical drugs

Cromolyn
Nedocromil

Mast cell stabilizers are medications used to prevent or treat certain allergic disorders. They block degranulation of mast cells, stabilizing it and thereby preventing the release of histamine and related mediators. One suspected pharmacodynamic mechanism is the blocking of IgE-regulated calcium channels. Without intracellular calcium, the histamine vesicles cannot fuse to the cell membrane and degranulate.[1]

As inhalers they are used to treat asthma, as nasal sprays to treat hay fever (allergic rhinitis) and as eye drops for allergic conjunctivitis.[2] Finally, in oral form, they are used to treat the rare condition of mastocytosis.[3][4]

Examples

[edit]

Mast cell stabilizer medications include:

  • cromoglicic acid (cromolyn/cromoglycate)[5][6][1][7][4]
  • ketotifen[1][7][8][9]
  • lodoxamide[4][10]
  • nedocromil[10][11]
  • pemirolast[4]
  • olopatadine[12]

Research

[edit]

The following substances are studied on their potential mast cell stabilizing effects, but the current results are inconclusive:

  • vitamin D[13]
  • quercetin[14]

References

[edit]
  1. ^ a b c Finn DF, Walsh JJ (September 2013). "Twenty-first century mast cell stabilizers". Br J Pharmacol. 170 (1): 23–37. doi:10.1111/bph.12138. PMC 3764846. PMID 23441583.
  2. ^ Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A (2015). "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis". Cochrane Database Syst Rev. 2015 (6) CD009566. doi:10.1002/14651858.CD009566.pub2. hdl:2164/6048. PMC 10616535. PMID 26028608.
  3. ^ Castells M, Butterfield J (April 2019). "Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management". J Allergy Clin Immunol Pract. 7 (4): 1097–1106. doi:10.1016/j.jaip.2019.02.002. PMID 30961835.
  4. ^ a b c d Chadwick SJ (15 May 2009). "Principles of Allergy Management". Managing the Allergic Patient. pp. 19–72. doi:10.1016/B978-141603677-7.50006-6. ISBN 978-1-4160-3677-7. Sodium cromoglycate (cromolyn sodium) has now been available in an intranasal format OTC for almost 10 years[...] Nedocromil is much more potent [...] Other ophthalmic mast cell stabilizers include cromolyn sodium, ketotifen, and pemirolast, and topical antihistamines such as olopatadine also demonstrate mast-cell stabilizing effects. Cromolyn sodium is also used as an oral preparation for the treatment of mastocytosis and has been used off-label in the management of food allergy
  5. ^ Wang Y, Liu Z, Zhou W, Wang J, Li R, Peng C, et al. (February 2024). "Mast cell stabilizer, an anti-allergic drug, reduces ventricular arrhythmia risk via modulation of neuroimmune interaction". Basic Res Cardiol. 119 (1): 75–91. doi:10.1007/s00395-023-01024-y. PMID 38172251.
  6. ^ "Mast cell stabilizers". drugs.com. Retrieved 2 April 2023.
  7. ^ a b Zhang L, Song J, Hou X (April 2016). "Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside". J Neurogastroenterol Motil. 22 (2): 181–92. doi:10.5056/jnm15137. PMC 4819856. PMID 26755686.
  8. ^ Nwaru BI, Dhami S, Sheikh A (2017). "Idiopathic Anaphylaxis". Curr Treat Options Allergy. 4 (3): 312–319. doi:10.1007/s40521-017-0136-2. PMC 5569651. PMID 28890861.
  9. ^ El-Alali EA, Abukhiran IM, Alhmoud TZ (July 2021). "Successful use of montelukast in eosinophilic gastroenteritis: a case report and a literature review". BMC Gastroenterol. 21 (1) 279. doi:10.1186/s12876-021-01854-x. PMC 8265096. PMID 34238222.
  10. ^ a b Feuille EJ, Phipatanakul W, Permaul P (2022). "Conventional medications for the treatment of allergic rhinitis and conjunctivitis". Allergic and Immunologic Diseases. pp. 1077–1109. doi:10.1016/B978-0-323-95061-9.00038-2. ISBN 978-0-323-95061-9. Evidence is insufficient to compare the efficacy of available ocular mast cell stabilizers (cromolyn, lodoxamide, nedocromil)
  11. ^ Chu R, Bajaj P (2025). Asthma Medication in Children. PMID 28722853.
  12. ^ Kowtharapu LP, Katari NK, Sandoval CA, Konduru N, Muchakayala SK, Pydimarry SP, et al. (June 2023). "Regulatory Perspective Reverse Engineering Analysis of the Mast Cell Stabilizer and the Histamine Receptor Antagonist (Olopatadine HCl): Instrumental and Classical Methods for Multiple Formulations". ACS Omega. 8 (24): 21485–21492. doi:10.1021/acsomega.3c00311. PMC 10285952. PMID 37360430.
  13. ^ Lui ZQ, Lii XX, Qui ZQ, Yu Y, Li MG (2017). "Vitamin D contributes to mast cell stabilization". Allergy. 72 (8): 1184–1192. doi:10.1111/all.13110. PMID 27998003. S2CID 4643742.
  14. ^ Weng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, Fu X, et al. (28 March 2012). "Quercetin Is More Effective than Cromolyn in Blocking Human Mast Cell Cytokine Release and Inhibits Contact Dermatitis and Photosensitivity in Humans". PLOS ONE. 7 (3) e33805. Bibcode:2012PLoSO...733805W. doi:10.1371/journal.pone.0033805. PMC 3314669. PMID 22470478.
  • v
  • t
  • e
Drugs for obstructive airway diseases: asthma/COPD (R03)
Adrenergics, inhalants
Short-acting β2 agonists
  • Bitolterol
  • Carbuterol
  • Fenoterol
  • Isoetarine
  • Pirbuterol
  • Procaterol
  • Reproterol
  • Rimiterol
  • Salbutamol (albuterol)#/Levosalbutamol (levalbuterol)
  • Terbutaline
  • Tulobuterol
Long-acting β2 agonists
  • Bambuterol
  • Clenbuterol
  • Formoterol/Arformoterol
  • Salmeterol
Ultra-long-acting β2 agonists
  • Abediterol
  • Carmoterol
  • Indacaterol
  • Olodaterol
  • Vilanterol
Other
  • Clorprenaline
  • Ephedrine (+theophylline, +theophylline/phenobarbital, theophylline/hydroxyzine)
  • Epinephrine#
  • Etafedrine
  • Hexoprenaline
  • Isoprenaline (isoproterenol)
  • Methylephedrine
  • Orciprenaline (metaproterenol)
  • Racephedrine
  • Tretoquinol
Glucocorticoids
  • Beclometasone#
  • Betamethasone#
  • Budesonide
  • Ciclesonide
  • Flunisolide
  • Fluticasone propionate
  • Mometasone
  • Triamcinolone
Anticholinergics/
muscarinic antagonist
  • Aclidinium bromide
  • Glycopyrronium bromide
  • Ipratropium bromide#
  • Oxitropium bromide
  • Tiotropium bromide
  • Umeclidinium bromide
Mast cell stabilizers
  • Cromoglicate
  • Nedocromil
Xanthines
  • Acefylline
  • Ambuphylline
  • Aminophylline
  • Bamifylline
  • Choline theophyllinate
  • Doxofylline
  • Enprofylline
  • Etamiphylline
  • Proxyphylline
  • Theophylline
Eicosanoid inhibition
Leukotriene antagonists
  • Montelukast
  • Pranlukast
  • Zafirlukast
Arachidonate 5-lipoxygenase inhibitors
  • Zileuton
Thromboxane receptor antagonists
  • Ramatroban
  • Seratrodast
Non-xanthine PDE4 inhibitors
  • Ibudilast
  • Roflumilast
Others/unknown
  • Amlexanox
  • Ensifentrine
  • Eprozinol
  • Fenspiride‡
  • Omalizumab
Combination products
  • Aclidinium bromide/formoterol
  • Beclometasone/formoterol
  • Beclometasone/formoterol/glycopyrronium bromide
  • Budesonide/formoterol
  • Budesonide/glycopyrronium bromide/formoterol
  • Fluticasone furoate/umeclidinium bromide/vilanterol
  • Fluticasone furoate/vilanterol
  • Fluticasone propionate/salmeterol
  • Glycopyrronium bromide/formoterol
  • Indacaterol/glycopyrronium bromide
  • Indacaterol/glycopyrronium bromide/mometasone
  • Indacaterol/mometasone
  • Ipratropium bromide/salbutamol
  • Mometasone/formoterol
  • Salbutamol (albuterol)/budesonide
  • Theophylline/ephedrine
  • Theophylline/ephedrine/hydroxyzine
  • Theophylline/ephedrine/phenobarbital
  • Umeclidinium bromide/vilanterol
  • #WHO-EM
  • ‡Withdrawn from market
  • Clinical trials:
    • †Phase III
    • §Never to phase III
  • v
  • t
  • e
Decongestants and other nasal preparations (R01)
Topical
Sympathomimetics, plain
  • Amidephrine
  • Cyclopentamine
  • Ephedrine
  • Epinephrine
  • Fenoxazoline
  • Iproheptine
  • Levmetamfetamine
  • Methylephedrine
  • Metizoline
  • Naphazoline
  • Oxymetazoline
  • Phenylephrine
  • Propylhexedrine
  • Tetryzoline
  • Tramazoline
  • Tuaminoheptane
  • Tymazoline
  • Xylometazoline
Antiallergic agents,
excluding corticosteroids
  • Spaglumic acid
  • histamine antagonists (Levocabastine
  • Antazoline
  • Thonzylamine)
  • mast cell stabilizer (some are also antihistamines) (Cromoglicic acid
  • Nedocromil
  • Azelastine
  • Olopatadine
  • Lodoxamide)
Corticosteroids
  • Beclometasone dipropionate
  • Betamethasone#
  • Budesonide
  • Ciclesonide
  • Dexamethasone
  • Flunisolide
  • Fluticasone (Fluticasone furoate, Fluticasone propionate)
  • Mometasone furoate
  • Prednisolone#
  • Tixocortol
  • Triamcinolone
  • Triamcinolone acetonide
Other nasal preparations
  • Cafaminol
  • Calcium hexamine thiocyanate
  • Eucalyptus oil
  • Framycetin
  • Hexamidine
  • Hyaluronan
  • Ipratropium bromide
  • Mupirocin
  • Retinol
  • Ritiometan
  • Saline water
Combination products
  • Olopatadine/mometasone
Systemic use:
Sympathomimetics
  • Ephedrine
  • Phenylephrine
  • Phenylpropanolamine‡
  • Pseudoephedrine (+azatadine, +carbinoxamine, +cetirizine, +dexbrompheniramine, +fexofenadine, +loratadine, +naproxen)
  • #WHO-EM
  • ‡Withdrawn from market
  • Clinical trials:
    • †Phase III
    • §Never to phase III
Stub icon

This drug article relating to the respiratory system is a stub. You can help Wikipedia by adding missing information.

  • v
  • t
  • e
Retrieved from "https://teknopedia.ac.id/w/index.php?title=Mast_cell_stabilizer&oldid=1337654104"
Categories:
  • Mast cell stabilizers
  • Respiratory system drug stubs
Hidden categories:
  • Articles with short description
  • Short description matches Wikidata
  • Use dmy dates from December 2024
  • All stub articles

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id